Nastech acquires Galenea RNAi program

Galenea ( Cambridge, Mass.) granted NSTK exclusive rights to RNAi therapeutics against influenza and other respiratory infections. The lead compound is G00101, an inhaled RNAi therapeutic that NSTK sa...